On October 11, 2023, MarketWatch, among many other news outlets, reported the trial success of Novo Nordisk’s hit drug Ozempic against kidney failure. Fresenius shares dropped by almost one-fourth as a result. Luckily, we sold our 500 shares of Fresenius (FMS) back on August 11, 2023, when it was trading at $26.16 for over $4000.00 capital gain.
You may read the original Marketwatch article cited here, and more general reporting at the link in the lead sentence. The point of this short blog entry is to apprise readers of changes afoot in the dialysis arena. The train is coming!
Leave a Reply